Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411525 · ClinicalTrials.gov registry record · NA
Effects of Provider Commitments to Choose Wisely
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 489
- Enrollment target
NCT03411525: Completed NA study, sponsored by University of Michigan.
NCT03411525 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 489 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03411525, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 489 participants
- Enrollment target
Study Summary
Clinicians' decisions to order potentially unnecessary services -- such as those targeted in the Choosing Wisely® campaign -- are often affected by their high-pressure practice environments, which can make it hard to consistently avoid ordering low-value care. The field of behavioral economics offers a promising and highly scalable approach to decreasing use of low-value services: asking clinicians to commit to avoid ordering such services and providing them and their patients with resources to support adherence to this commitment. This project will evaluate the effects of such an intervention across 2 large health systems, Michigan Medicine and IHA, through a mixed-methods, stepped wedge cluster randomized trial. In each of the study clinics, clinicians will be invited to commit to following a set of targeted Choosing Wisely® recommendations. Clinicians who make such a commitment, and their patients, will receive access to key resources to support adherence to this commitment. To measure the effects of the intervention, automated clinical data and medical record data before and after the intervention will be examined. Surveys and semi-structured interviews of both clinicians and patients will also be conducted to determine the effects of the intervention on their decision-making and experiences.
Primary Outcome
The applicable low-value treatments or tests specified by the respective Choosing Wisely® recommendations are use of hypoglycemic medications for patients 65 years or older with diabetes and tight glycemic control, PSA testing among men 75 years or older with no history of prostate cancer, and use of benzodiazepine or sedative-hypnotic medications for patients with insomnia or anxiety who are 65 years or older.
Interventions
- BEHAVIORAL Commitment Invitation for Clinicians (Clinician Intervention)
- OTHER Health Education Materials to Patients (Patient Intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2019-02-28 |
| Phase | NA |
What the finished NCT03411525 record still lists
NCT03411525 is an interventional study that assigns participants to a tested intervention. The registered 489 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Commitment Invitation for Clinicians (Clinician Intervention) is the first listed.
NCT03411525 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03411525 about?
NCT03411525 is a clinical study titled "Effects of Provider Commitments to Choose Wisely". Clinicians' decisions to order potentially unnecessary services -- such as those targeted in the Choosing Wisely® campaign -- are often affected by their high-pressure practice environments, which can make it hard to consistently avoid ordering low-value care. The field of behavioral economics offer...
What is the current status of trial NCT03411525?
This trial is currently completed. It is a NA study. The enrollment target is 489 participants. The study started on 2018-01-26. Estimated completion is 2019-02-28.
What interventions are being tested in trial NCT03411525?
The interventions under investigation include: Commitment Invitation for Clinicians (Clinician Intervention) (BEHAVIORAL), Health Education Materials to Patients (Patient Intervention) (OTHER).
Who is sponsoring clinical trial NCT03411525?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03411525's enrollment target sits among peer trials
489 215th of 2000 higher than 1,786 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI